What if AI were deployed at something that actually deserves to go away? Something like…say…cancer? Early-stage cancer cells can be thought of like “malware” affecting the “software” in the body. Insidious. Rogue. Difficult to detect. At Astrin, we’re building the AI-enabled “security system” to identify cancer at the earliest stage possible. With proteomic technology, harnessed by AI, we’re putting humankind’s most powerful innovations toward real-life outcomes that matter. Read more about our cancer detection blood-test today in TechCrunch: https://lnkd.in/dZSnG95h
Astrin Biosciences
Biotechnology Research
St. Paul, MN 770 followers
Deep Learning-Empowered Early Cancer Detection
About us
Astrin Biosciences is a cancer intelligence company built to push the boundaries of technology – accelerating early detection and advancing cancer care. Astrin’s breakthrough cancer tests analyze the early signals in over 8,000 proteins to reveal what most tests miss: the earliest molecular signals in cancer development. Astrin Biosciences was founded on a bold idea: that health decisions should be based not just on what’s happening inside the body, but on the reality of the person living in it. Our Mission us to lead in cancer intelligence and early detection.
- Website
-
http://astrinbio.com
External link for Astrin Biosciences
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- St. Paul, MN
- Type
- Privately Held
- Founded
- 2021
- Specialties
- oncology, biotechnology, AI, Machine Learning, precision medicine, start-up, metastasis, early stage, proteomics, liquidbiopsy, deeplearning, Cancer screening , Breast Cancer, and Blood Test
Locations
-
Primary
St. Paul, MN 55114, US
Employees at Astrin Biosciences
Updates
-
Breast cancer screenings are meant to bring clarity, not confusion. For women with dense breast tissue, mammograms can sometimes leave more questions than answers. At Astrin, we’re pioneering a new approach — using deep proteomics and AI to detect early signs of cancer through a simple blood test, designed to bring greater accuracy and confidence to every screening experience. Our CEO, Jayant Parthasarathy, and Chief Medical Officer, Dr. Badrinath Konety, share this vision in their new piece for STAT. Read it here ⬇️ : https://lnkd.in/eE4KUtJE
-
With advancements in proteomics, we now stand on the forefront of detecting early-stage cancer with higher accuracy. Markers of cancer are extremely challenging to detect. Plasma is dominated by a few highly abundant proteins, which mask subtler proteins that may be signaling cancer. We’re proud to continue the innovative streak in proteomics. Every day our technology gets closer—and therefore earlier.
-
-
Now that’s a team focused on one mission. 🩷 This #BreastCancerAwarenessMonth, we’re proud to be unified in the fight against breast cancer. At Astrin Biosciences, we are leveraging the promise of proteomic research to further develop blood tests that identify cancer signals at the earliest stage possible. Want to stay up-to-speed on our job openings, research breakthroughs, and more? Join our email update list here —> https://lnkd.in/eZxB5ztT
-
-
Proteins make the world go ‘round. (Or at very least, they make us go ‘round). At Astrin Biosciences, we’re putting proteomics (the study of proteins) to work to help facilitate early, accurate, and critical detection of breast cancer. We are able to analyze over 9,000 proteins at once, making for a comprehensive cancer detection test unlike any other. Blood draw —> Centrifuge —> AI classification —> Result
-
-
Hope has never been stronger, The light has never been brighter, Together we're unstoppable, The end of cancer has never been closer. This month; please consider donating to these incredible organizations fighting the good fight: Surviving Breast Cancer: https://lnkd.in/gB4w_ZSe My Density Matters: https://lnkd.in/eJktKMW The Brem Foundation: https://lnkd.in/eGVi3cC4 BCRF: https://www.bcrf.org Susan G Komen: https://www.komen.org Or supporting researchers Ben Ho Park, MD, PhD, Margarita Zuley MD, Adrian Lee, Pooja Advani MD, Fergus Couch, PhD, Sandhya Pruthi, William Morice II, MD, PhD, Julio Aguirre-Ghiso, Nilay Sethi, Emmanuel S. Antonarakis, M.D., Samir Zaidi, Antti Rannikko, Justin Drake, Ph.D., Forest White, Badrinath Konety and countless others who have all devoted their lives and careers to bring us that much closer to defeating cancer in its various shape shifting forms.
Awareness is just the beginning. *Action* takes us from bystanders to warriors. This #BreastCancerAwarenessMonth, we are working to fulfill the calling behind the World Health Organization’s #BCAM2025 theme: “Every story is unique. Every journey matters.” Leveraging the powerful promise of proteomics, we are working to identify breast cancer at Stage Zero. Our individualized and tailored approach identifies early markers of cancer within proteins. It’s the type of targeted detection that supports people with dense breast tissue (over half of women over 40 years old) who cannot rely on a mammogram to detect cancer. Detection is not one-size-fits-all. For each and every person at risk of breast cancer, let’s look closer—and discover the importance of detecting meaningful diagnoses way earlier.
-
-
Awareness is just the beginning. *Action* takes us from bystanders to warriors. This #BreastCancerAwarenessMonth, we are working to fulfill the calling behind the World Health Organization’s #BCAM2025 theme: “Every story is unique. Every journey matters.” Leveraging the powerful promise of proteomics, we are working to identify breast cancer at Stage Zero. Our individualized and tailored approach identifies early markers of cancer within proteins. It’s the type of targeted detection that supports people with dense breast tissue (over half of women over 40 years old) who cannot rely on a mammogram to detect cancer. Detection is not one-size-fits-all. For each and every person at risk of breast cancer, let’s look closer—and discover the importance of detecting meaningful diagnoses way earlier.
-
-
For so many people, early detection of breast cancer may require additional testing beyond the mammogram. Thank *you* for spreading the word about breast density and cancer risk, Brem Foundation! #WorldDenseBreastDay Brem Foundation to Defeat Breast Cancer
Thank you New York Post and our friends at Astrin Biosciences for highlighting Brem’s CheckMate breast cancer risk quiz (bremfoundation.org/quiz) Today is World Dense Breast Day, and this article breaks down what you need to know about breast density and how it increases breast cancer risk. Finding cancer is harder on a mammogram of dense tissue and you may need additional testing to maximize chances of early detection of cancers. Taking a risk assessment quiz, CheckMate, helps you understand your own risk factors and come up with a screening plan with your doctor that’s best for you. Learn more to take charge of your breast health: https://lnkd.in/erBdzX5r
-
This week we honored #WorldDenseBreastDay by working to get the word out about breast density. Thanks to the FDA National Dense Breast Reporting, healthcare providers are now required to tell patients about their breast density at their mammogram. This means the question, “Do you have a family history of cancer?” isn’t the only one required at a mammogram. In addition, doctors should be asking, “Do you know if you have dense breast tissue?” Breast density can make it difficult to identify cancer. That’s why we’re pioneering technology in proteomics to develop alternative tools that help people with dense breast tissue identify breast cancer earlier. Learn more about how you can raise awareness for breast density by visiting densebreast-info.org
-
-
It’s #WorldDenseBreastDay and we're proud to see our Chief Medical Officer, Badrinath Konety, speaking to this often overlooked—but critical—aspect of breast health in the New York Post today. With nearly half of U.S. women over 40 having dense breast tissue, we need to be innovating to find breast cancer earlier, faster, and more reliably. At Astrin, we’re working to be that innovation, developing a blood test that will detect cancer signals across all breast densities – including those that are extremely dense. Thrilled to see our efforts highlighted here, and can’t wait to see the impact our work will have on awareness and options for women with dense breasts by the time the next World Dense Breast Day arrives. Read more here: https://lnkd.in/erBdzX5r
"Know your density, understand your options, and don't accept 'come back next year' if you're uncomfortable with mammography's limitations in dense tissue." Beautifully said, Badrinath Konety, and grateful to the New York Post for advocating on behalf of millions of women with dense breasts. Your health. Your body. Refuse to settle for screening that doesn't work for you! #WorldDenseBreastDay Read the full piece and share it with the women in your life to help them stay on top of the right screenings for them: https://lnkd.in/gnEPF8HX